Home
Mail
Search
News
Finance
Sport
Lifestyle
Celebrity
Movies
Weather
Mobile
More
Yahoo
Mail
Cryptocurrencies
News
Property
Money
Markets
Industries
Watchlists
My Portfolio
My Screeners
Singapore markets closed
Straits Times Index
3,292.93
-3.96
(-0.12%)
Nikkei
38,236.07
-37.98
(-0.10%)
Hang Seng
18,475.92
+268.79
(+1.48%)
FTSE 100
8,208.49
+36.34
(+0.44%)
Bitcoin USD
59,213.25
+686.09
(+1.17%)
CMC Crypto 200
1,279.63
+2.65
(+0.21%)
Pacira BioSciences, Inc. (PCRX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
27.32
+0.37
(+1.37%)
At close: 04:00PM EDT
27.32
0.00
(0.00%)
After hours:
04:02PM EDT
Summary
Chart
Statistics
Historical data
Profile
Financials
Analysis
Options
Holders
Sustainability
Show
:
Income statement
Balance sheet
Cash flow
Annual
Quarterly
Income statement
All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
674,978
674,978
666,823
541,533
429,647
Cost of revenue
184,669
184,669
199,295
140,255
117,328
Gross profit
490,309
490,309
467,528
401,278
312,319
Operating expenses
Research development
76,257
76,257
84,797
55,545
59,421
Selling general and administrative
269,441
269,441
254,516
199,345
193,516
Total operating expenses
402,986
402,986
396,601
268,443
260,803
Operating income or loss
87,323
87,323
70,927
132,835
51,516
Interest expense
17,310
17,310
35,576
28,996
23,515
Total other income/expenses net
-16,760
-16,760
-22,191
-45,577
-10,385
Income before tax
61,701
61,701
13,302
56,404
20,089
Income tax expense
19,746
19,746
-2,607
14,424
-125,434
Income from continuing operations
41,955
41,955
15,909
41,980
145,523
Net income
41,955
41,955
15,909
41,980
145,523
Net income available to common shareholders
41,955
41,955
15,909
41,980
145,523
Basic EPS
0.15
0.91
0.35
0.95
3.41
Diluted EPS
0.15
0.89
0.34
0.92
3.33
Basic average shares
46,084
46,222
45,521
44,262
42,671
Diluted average shares
46,084
51,979
46,538
45,630
43,682
Data disclaimer
Help
Suggestions
Terms
and
Privacy Policy
Privacy dashboard
About our ads
© 2024 Yahoo. All rights reserved.